skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

287 Total results for product and free and sample content found

Pink Sheet

Generic Industry Hit With Avalanche Of Price Fixing Suits

By Brenda Sandburg 23 Feb 2017

As state attorneys general and Department of Justice move against generic manufacturers, plaintiffs’ firms have filed more than 90 antitrust suits.

Topic BioPharmaceutical Policy and regulation

Clinical and Research Excellence

CARE Awards Shortlist 2017

23 Feb 2017

We are delighted to announce the finalists for the 2017 Clinical and Research Excellence Awards.

Topic Clinical trials blog Clinical trials

Datamonitor Healthcare

Systemic Lupus Erythematosus Marketed and Pipeline Profiles Research Wire

By Manoli Kavishwar 22 Feb 2017

Enthusiasm following Benlysta's approval has died down, and there remains a considerable need for effective biologic therapies.

Topic Drug review

Scrip

Bayer Bets On Oncology Pipeline Vows To Increase 2017 R&D Budget

By Lucie Ellis 22 Feb 2017

Bayer has launched an internal oncology R&D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.

Topic Cancer Research

In Vivo

Cystic Fibrosis: Successes, Opportunities And Challenges

By Lucie Ellis 22 Feb 2017

What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.

Topic Clinical trials

Datamonitor Healthcare

EPOCH failure reveals more about clinical trial design

16 Feb 2017

In February 2017, Merck & Co announced the discontinuation of verubecestat’s Phase II/III study, EPOCH, in mild to moderate Alzheimer’s disease due to the high likelihood of missing the primary endpoint.

Topic Alzheimers

Scrip

eTheRNA CEO outlines development plan in cancer RNA space

15 Feb 2017

Mike Ward, global director of content for Informa Pharma Intelligence, interviews Dirk Reyn, CEO of eTheRNA, on the sidelines of the BIO-Europe partnering conference in Cologne, Germany. The pair discusses eTheRNA's emerging cancer immunotherapy pipeline, funding prospects and the next steps for the company—which was founded in 2013—as it looks to expand its business.

Datamonitor Healthcare

Chronic Lymphocytic Leukemia

By Dominique Fontanilla 15 Feb 2017

While Rituxan-based therapies remain dominant in the first-line treatment setting for early- and late-stage chronic lymphocytic leukemia (CLL), the majority of patients with relapsed or refractory disease receive Imbruvica. 

Topic Research wire

Trialtrove

A Bird’s-Eye View of the Rare Disease Landscape

14 Feb 2017

Over 350 million people worldwide are suffering from rare diseases. Which is why it is necessary to understand the rare disease landscape to date.

Topic Clinical trials Diseases

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: